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Poster Session II S291was faster after PBSCT than BMT (neutrophils 14.5 d versus 18.0 d,
p\0.001; platelets, 23.1 d versus 28.7 d, p5 0.034). The cumulative
incidence of grade II – IV acute graft-versus-host-disease at 100 days
was 10.4% after PBSCT and 15.1% after BMT (p5NS). The cu-
mulative incidence of chronic graft-versus-host disease was 13.8%
after PBSCT and 11.3% after BMT (p5NS). Standard disease
risk was defined as ALL or AML in first or second remission or
with unfavorable prognoses. The high risk category was confined
in third or subsequent remission or in relapse. One year disease-
free survival in standard risk disease was 61.5% after PBSCT and
81.3% after BMT (p5NS). In high risk disease, 1 year survival
was 18.8% after PBSCT and 25.8% after BMT (p5NS). In multi-
variate analysis, only disease risk and pre-transplant CMV seroposi-
tivity were significant predictors of disease-free survival. HLA
typing, CD 34 depletion, and occurrence of acute or chronic
GvHD were included as independent variables but were not signifi-
cant prognostic factors associated with treatment-related mortality,
relapse or disease-free survival. We conclude that PBSCT for chil-
dren produces faster engraftment without increased risk of acute
or chronic GvHD.360
REDUCED-INTENSITY ALLOGENEIC BONE MARROW TRANSPLANTATION
WITHOUT INCLUSION OF TOTAL BODY IRRADIATION FOR A CHILDWITH
DYSKERATOSIS CONGENITA
Powell, J.L., Frantz, C.N., Kolb, E.A. Alfred I. duPont Hospital for Chil-
dren, Wilmington, DE
A 20 month old, ex 33 week gestation male with a history of cere-
bral palsy, retinopathy of prematurity, moderate developmental de-
lay, and periventricular leukoencephalopathy presented during
a febrile episode with a platelet count of 102 k/ml. A CBC obtained
8 months previously had a platelet count of 508 k/ml with otherwise
normal white count and hemoglobin. Over the course of his hospital-
ization, his platelet count fell to 41 k/microliter. His hemoglobin was
10.6 g/dL with an MCV of 93 fL; his white blood cell count was
3.6 k/microliter. His thrombocytopenia continued to worsen, and
he developed neutropenia\750 k/microliter. Physical examination
included dystrophic finger/toe nails. Evaluation for for dyskeratosis
congenita via telomere length measurement was obtained. He was
found to have a median telomere length of 7.9 kb for his lymphocytes
and 8.9 kb for his granulocytes, both of which are very low in com-
parison to laboratory established normals. DKC1, TERC, and
TERT gene evaluations revealed no mutation. Pancytopenia wors-
ened rapidly (hemoglobin \7 g/dL, ANC\0.5 k/microliter,
platelets\10 k/microliter), and we decided to pursue stem cell
transplantation. He received a reduced intensity transplant using flu-
darabine (25 mg/m2/q 24 hours  5 doses on days -7 to -3), cyclo-
phosphamide (400 mg/m2 q 24 hours  4 doses on days -6 to -3),
rabbit ATG (3.75 mg/kg q 24 hours  4 doses on days -5 to -2).
GVH prophylaxis was provided with cyclosporine and methotrexate.
He received a 10/10 matched unrelated bone marrow transplant.
Donor and recipient were both CMV negative. Transplant was
well tolerated by the patient except for allergic reactions to ATG.
The patient experienced grade II skin GVH, treated with cyclospor-
ine and prednisolone. Neutrophil engraftment occurred on day +12;
platelet engraftment occurred on day +25, and red cell engraftment
by day +37. The patient was discharged to home on day +25. Engraft-
ment studies have remained 100% donor from day +12 to the most
recent examination on day +370. The patient has had resolution of
his cytopenias. This patient represents the first US report of
a non-radiation containing, reduced intensity transplant regimen
for a patient with dyskeratosis congenita.361
THE DURATION OF THE EX VIVO TRANSPORTATION OF HEMATOPOIETIC
STEM CELLS DOES NOT SEEM TO IMPAIR THE CLINICAL OUTCOME FOL-
LOWING TRANSPLANTATION – A SINGLE CENTRE STUDY
Olsson, R., Remberger, M., Ringden, O. Karolinska University Hospital,
Stockholm, Sweden
In hematopoietic stem cell transplantation (HSCT), using un-
related donors, stem cells are often harvest at remote hospitals,and may be handled ex vivo for several days before they are in-
fused into the recipient. Thus, the aim of this study was to inves-
tigate whether the duration of the ex vivo transportation of
hematopoietic stem cells impairs the clinical outcome following
transplantation. We retrospectively analyzed 90 consecutive pa-
tients who received unrelated donor hematopoietic stem cells at
our centre between 2003 and 2008. Both children and adults
were included (median age 45, range 0.5-67), whereas retrans-
plantations were excluded. The indications for allogeneic
HSCT were: AML (32%), ALL (16%), myelodysplastic syn-
drome (16%), CML (10%), lymphoma (12%), solid tumors
(7%), metabolic disorders (3%), aplastic anemia (2%), and multi-
ple myeloma (2%). In all recipients, the total ex vivo time of the
stem cell transplant (median 28 h, range 5-53 h) was calculated
and subdivided into the transportation time from the donor hos-
pital to our centre (median 20 h, range 3-38 h), as well as the
time from arrival at our hospital until the start of the stem cell
infusion (median 10 h, 0.5-26 h). In univariate analysis, none of
the ex vivo times were significant predictors of graft failure, re-
lapse, non-relapse mortality or overall survival. In conclusion,
the clinical outcome following HSCT seems to be independent
of the time the stem cell transplant is kept ex vivo for transpor-
tation purposes.362
HIGH RABBIT-ANTI-HUMAN THYMOCYTE GLOBULIN SERUM LEVELS
ARE ASSOCIATED WITH LOW LIKELIHOOD OF GRAFT-VS-HOST DISEASE
AND HIGH LIKELIHOOD OF POSTTRANSPLANT LYMPHOPROLIFERATIVE
DISORDER
Ugarte-Torres, A.1, Podgorny, P.J.1, Liu, Y.1, Russell, J.A.2, Storek, J.2
1University of Calgary, Calgary, AB, Canada; 2Alberta Health Services,
Calgary, AB, Canada
Background: Rabbit-anti-human T cell globulin (ATG) has the po-
tential to decrease the likelihood of graft-vs-host disease (GVHD) or
graft failure and to increase the likelihood of relapse or infections.
After a given ATG dose, serum ATG levels are variable, presumably
due to variable clearance.
Patients andMethods:We determined ATG levels on day 7 and 28
in 160 recipients of allogeneic marrow or blood stem cells, whose
conditioning included 4.5 mg/kg ATG (Thymoglobulin, Genzyme).
Median follow up was 419 days (range, 14-1519).
Results: Patients with grade 2-4 acute GVHD as well as patients
with extensive chronic GVHD had lower and patients with post-
transplant lymphoproliferative disorder (PTLD) had higher median
ATG levels on day 7 as well as day 28. In multivariate analysis, pa-
tients with day 7 ATG levels above 1.109 mg/ml had 0.38-fold risk
of developing grade 2-4 acute GVHD compared to patients with
lower ATG levels (p5 0.02), patients with day 7 levels above
0.673 mg/ml had 0.44-fold risk of developing extensive chronic
GVHD (p5 0.009), and patients with day 7 ATG levels above
1.436 mg/ml had 8.30-fold risk of developing PTLD (p5 .001).
There was no association of either day 7 or day 28 ATG levels
with relapse, non-PTLD infections or death. Association with graft
failure could not be evaluated due to only 4 graft failures in the
cohort.
Conclusion: Patients with slow clearance of ATG have a low risk of
acute and chronic GVHD but a high risk of PTLD.363
EARLY COMPLETE DONOR LYMPHOID CHIMERISMWITH FLUDARABINE,
MELPHALAN AND LOW DOSE (400 CGY) TOTAL BODY IRRADIATION RE-
DUCED INTENSITY CONDITIONING
Hepgur, M.1, Saito, N.2, Hahn, T.2, Starostik, P.3, Wallace, P.4,
Bambach, B.2, Higman, M.2, Dubel, K.2, McCarthy, P.2,
Battiwalla, M.2 1University at Buffalo, Buffalo, NY; 2Roswell Park Can-
cer Institute, Buffalo, NY; 3Roswell Park Cancer Institute, Buffalo, NY;
4Roswell Park Cancer Institute, Buffalo, NY
Background: Delayed acquisition of complete donor lymphoid
chimerism may contribute to relapse in 200 cGy total body
